文献速递胸部肿瘤

质子束放疗联合同步化疗治疗不可切除Ⅲ期非小细胞肺癌:2期研究最终结果

Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
PubMed 文献 · JAMA Oncol · 2017-08-10

这项开放标签、单组2期研究纳入64例不可切除ⅢA/ⅢB期非小细胞肺癌患者,接受卡铂-紫杉醇同步化疗与被动散射质子束放疗(74 Gy相对生物效应剂量)。中位总生存26.5个月,5年总生存29%,5年无进展生存22%;远处转移与局部区域复发分别为54%和28%,未发生急性或晚期5级毒性。

要点

  • 中位总生存26.5个月,5年总生存29%(95%CI 18%-41%)。
  • 5年无进展生存22%(95%CI 12%-32%),远处转移54%,局部区域复发28%。
  • 未发生急性或晚期5级毒性;急性2级和3级食管炎分别为28%和8%。

核心结论

  • 同步化疗联合质子束放疗治疗不可切除非小细胞肺癌相比历史光子放疗数据,提供了有希望的临床结局和毒性反应发生率。
  • 仍需进一步优化质子治疗,尤其是调强质子治疗。

研究设计与样本

  • 开放标签、单组分配的2期前瞻性研究,纳入64例患者并进行分析。
  • 纳入标准为不可切除、组织学确诊的ⅢA/ⅢB期非小细胞肺癌,卡氏功能状态评分70至100,诊断前6个月体重下降不超过10%。
  • 分期使用正电子发射断层扫描和/或计算机断层扫描,允许诱导化疗。
  • 所有患者接受同步化疗(卡铂-紫杉醇)和被动散射质子束放疗(74 Gy相对生物效应剂量)。
  • 全部患者中位随访27.3个月,生存者中位随访79.6个月。

主要发现

  • 64例患者中22例(34%)为女性,中位年龄70岁(范围37-78岁),ⅢA期30例(47%),ⅢB期34例(53%)。
  • 末次随访时17例(27%)存活,中位总生存26.5个月,5年总生存29%(95%CI 18%-41%)。
  • 5年无进展生存22%(95%CI 12%-32%),5年 actuarial 远处转移54%(n=36),局部区域复发28%(n=22)。
  • 治疗失败主要为远处转移(31例,48%),粗局部复发10例(16%),区域复发9例(14%)。
  • 急性2级和3级食管炎分别为18例(28%)和5例(8%),急性2级肺炎1例(2%);晚期毒性少见,包括2级食管狭窄1例(2%)、4级食管炎1例(2%)、2级和3级肺炎分别为10例(16%)和8例(12%)、2级支气管狭窄2例(3%)、4级支气管瘘1例(2%),无急性或晚期5级毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proton beam radiotherapy (PBT) has the potential to reduce toxic effects in the definitive management of locally advanced non-small cell lung cancer (NSCLC), but long-term prospective data are lacking. OBJECTIVE: To report the final (5-year) results of a prospective study evaluating concurrent chemotherapy and high-dose PBT to treat unresectable stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: In this open-label, single-group assignment study, with median follow-up of 27.3 months for all patients and 79.6 months for survivors, 64 patients were enrolled and analyzed; inclusion criteria were unresectable IIIA/IIIB histologically confirmed NSCLC, Karnofsky performance status 70 to 100, and 6-month prediagnosis weight loss of no more than 10%. Staging used positron emission tomography and/or computed tomography. Induction chemotherapy was allowed. INTERVENTIONS: Concurrent chemotherapy (carboplatin-paclitaxel) and passively scattered PBT (74-Gy relative biological effectiveness) in all patients. MAIN OUTCOMES AND MEASURES: Kaplan-Meier analysis of overall survival (OS), progression-free survival (PFS), actuarial distant metastasis, and locoregional recurrence. Patterns of treatment failure were categorized as local/regional or distant. Acute and late toxic effects were prospectively assigned using Common Terminology Criteria for Adverse Events, v3.0. RESULTS: Of 64 patients (22 [34%] female; median [range] age, 70 [37-78] years; stage IIIA, 30 [47%]; IIIB, 34 [53%]), 17 (27%) were alive at last follow-up. Median OS was 26.5 months (5-year OS, 29%; 95% CI, 18%-41%). Five-year PFS was 22% (95% CI, 12%-32%); 5-year actuarial distant metastasis and locoregional recurrence were 54% (n = 36) and 28% (n = 22), respectively. Treatment failures were largely (31 [48%] patients) distant, with low rates of crude local (10 [16%]) and regional (9 [14%]) recurrences. Rates of grade 2 and 3 acute esophagitis were 18 (28%) and 5 (8%), respectively. Acute grade 2 pneumonitis occurred in 1 (2%) patient. Late toxic effects were uncommon: 1 (2%) patient developed an esophageal stricture (grade 2) and 1 (2%) grade 4 esophagitis. Late grades 2 and 3 pneumonitis occurred in 10 (16%) and 8 (12%), respectively. Two (3%) patients developed a bronchial stricture (grade 2), and 1 (2%) a grade 4 bronchial fistula. There were no acute or late grade 5 toxic effects. CONCLUSIONS AND RELEVANCE: Concurrent chemotherapy and PBT to treat unresectable NSCLC afford promising clinical outcomes and rates of toxic effects compared with historical photon therapy data. Further optimization of proton therapy, particularly intensity-modulated proton therapy, is still needed.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Chang JY, Verma V, Li M, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017. PMID: 28727865. doi:10.1001/jamaoncol.2017.2032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。